Solange Peters, MD, PhD, of the University of Lausanne, who has been a driving force in ESMO’s efforts to promote women in oncology, talks with Mary Gospodarowicz, MD, of Princess Margaret Hospital, a recipient of the 2017 Women Who Conquer Cancer Mentorship Award.
Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)
Daniel Heng, MD, MPH, of the Tom Baker Cancer Centre and the University of Calgary, and Sumanta K. Pal, MD, of the City of Hope, discuss key findings presented at ASCO: adjuvant pazopanib vs placebo after nephrectomy in patients with locally advanced disease (the PROTECT Trial), and adjuvant sunitinib used to treat high-risk disease.
Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)
Matthew D. Hellmann, MD, of Memorial Sloan Kettering Cancer Center, discusses study findings on nivolumab ± ipilimumab in advanced small cell lung cancer, in the first report of a randomized expansion cohort. (Abstract 8503)
Dean F. Bajorin, MD, of Memorial Sloan Kettering Cancer Center, and Peter H. O’Donnell, MD, of The University of Chicago Medical Center, discuss their study findings on treating advanced urothelial cancer with pembrolizumab, paclitaxel, docetaxel, or vinflunine. (Abstracts 4501 and 4502)
